Biogen Idec has announced that dexpramipexole, an experimental drug for the treatment of amyotrophic lateral sclerosis (ALS), commonly known as Lou Gehrig's disease, did not pass the Phase 3 clinical trial. The drug was not able to slow the loss of muscular function or lengthen the lifespan of patients with the condition... via Featured Health News from Medical News Today Read More Here..
No comments:
Post a Comment